⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616955 | 1.00 | — | — | |
| SCHEMBL7616952 | 1.00 | — | — | |
| SCHEMBL8436447 | 0.93 | LCK (0.39) | — | |
| SCHEMBL8088176 | 0.91 | LCK (0.42) | — | |
| SCHEMBL789095 | 0.84 | — | — | |
| SCHEMBL6054261 | 0.81 | ALDH1A1 (0.36) | — | |
| SCHEMBL28264594 | 0.80 | — | — | |
| SCHEMBL306336 | 0.78 | — | — | |
| SCHEMBL18757881 | 0.78 | — | — | |
| SCHEMBL3875750 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60142921-A | — | — | None | — | — | JP | disclosed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-0620225-B1 | Cephalosporin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-11-13 | — | — | EP | disclosed |
| US-5523400-A | 3-(PYRROLIDIN-3-YLIDENE=CH-),7-((2-AMINOTHIAZOL-4-YL)HYDROX -IMINOACETYLAMINO-)-3-CEPHEM DERIVATIVES; BROAD SPECTRUM ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0620225-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-10-19 | — | — | EP | disclosed |
| EP-0509005-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1992-10-21 | — | — | EP | disclosed |
| WO-1991010648-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| US-4892870-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, IMMUNOMODULATING AGENTS | BIOFOR, LTD. (US) | 1990-01-09 | — | — | US | disclosed |
| US-4789675-A | HYPOTENSIVE, ANTIISCHEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-06 | — | — | US | disclosed |
| CN-87100658-A | 1,4-benzoxazine derivatives, their preparation and application | — | 1987-09-09 | — | — | CN | disclosed |
| EP-0233728-A1 | 1,4-Benzoxazine derivatives their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-08-26 | — | — | EP | disclosed |
| JP-S60142921-A | ANTITUMOR AGENT | AJINOMOTO CO INC | 1985-07-29 | — | — | JP | disclosed |